Kemwell Biopharma & RevOpsis Partner to Expedite Biologic Development

This collaboration aims to fast-track the development of RevOpsis' lead candidate, RO-104, a novel tri-specific biologic designed to treat neovascular age-related macular degeneration (nAMD).

US-based RevOpsis Therapeutics, a next-generation biopharmaceutical startup, has entered a strategic manufacturing partnership with Bengaluru-based Kemwell Biopharma. 

This collaboration aims to fast-track the development of RevOpsis' lead candidate, RO-104, a novel tri-specific biologic designed to treat neovascular age-related macular degeneration (nAMD).

Advancing RO-104 for nAMD Treatment

RO-104 is a first-in-class tri-specific biologic targeting three dominant angiogenic pathways: VEGF-A, VEGF-C, and Ang-2. This treatment has the potential to significantly impact the landscape of retinal vascular disease therapy, particularly nAMD, which is a significant cause of blindness worldwide.

Kemwell Biopharma, known for its extensive experience in complex protein manufacturing, will produce RO-104. 

As India’s first commercial Good Manufacturing Practices (cGMP) manufacturing facility, Kemwell brings expertise and reliability. This partnership will leverage Kemwell's manufacturing capabilities and RevOpsis' Rev-Mod platform to streamline the development of multispecific biologics.

Accelerating Clinical Development

The alliance aims to swiftly transition RO-104 from pre-clinical activities to first-in-human clinical trials. By integrating RevOpsis' next-generation plug-and-play multispecific biologics platform with Kemwell’s biologics development and manufacturing knowledge, the collaboration is set to expedite therapeutic discovery and IND submission timelines.

In a statement, Dr James Baker, CEO of RevOpsis, said, "Our partnership with Kemwell is a significant step towards bringing our innovative therapies to patients faster. Their expertise in biologics manufacturing will be instrumental in advancing our lead candidate, RO-104, into clinical trials."

The collaboration highlights the importance of combining innovative biotechnology platforms with robust manufacturing processes to address unmet medical needs in ophthalmology. 

Founded in 1980 by Subhash Bagaria, Kemwell Biopharma operates as a contract pharmaceutical development and manufacturing organization (CDMO). It provides technology and manufacturing solutions to bio-pharmaceutical companies globally.